ClinicalTrials.gg
CompletedNCT04599088Updated Oct 5, 2026Results posted

Investigation of Brain Mechanisms Involved in the Urinary Continence Mechanism Associated With Aging

An interventional study of Brain functional MRI with simplified urodynamics in Urgency Urinary Incontinence, sponsored by University of Pittsburgh. Completed at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by University of Pittsburgh · Not applicable, Interventional, and Other

How we know · 2 judgments

Updated Oct 5, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
217
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 293 studies in Urinary Incontinence with a site in United States — 33 open to participants now, 47 under way, 3 of them phase 3. Urinary Incontinence · United States.

Enrollment
61st of 249
217 · median 75
Started
2020
with 13 others
No phase
144 of 293
21 open now
Registered
213th of 293
by date

Among the 293 studies in Urinary Incontinence with a site in United States, this one is the 61st largest by enrollment of the 249 interventional ones that give a count, is one of 14 that started in 2020, is one of 144 with no phase, and was the 213th registered.

Urinary Incontinence

988 studies on the registry are indexed under Urinary Incontinence; 184 are open to participants now.

Browse Urinary Incontinence studies →

Open to participants now

33 of the 293 studies in Urinary Incontinence with a site in United States are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 113 Urinary Incontinence studies recruiting now, 63 (56%) set no upper age limit and 35 (31%) stop at 75 or younger; 15 take children under 18; 28 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 293 studies in Urinary Incontinence with a site in United States, or all of them as a file.
02

Study summary

Urge urinary incontinence (UUI) is a common problem in older people which vastly reduces quality of life, yet the cause and mechanism of disease are not well understood. This study will characterize brain control of the bladder in young and old continent individuals and age-matched incontinent counterparts. This will expand the investigators current knowledge of how the brain controls the bladder, how that control changes with age and disease, and suggest new targets to guide development of better treatment.

Read the detailed description

Current data suggest that bladder control comprises 3 cerebral circuits that maintain continence by suppressing the voiding reflex in the midbrain. In the UUI phenotype that responded to BFB (Biofeedback assisted pelvic floor muscle therapy), the mechanism involved enhancing deactivation of the first brain circuit (medial prefrontal cortex, mPFC) which resulted in less activation of the second circuit (which includes the midcingulate cortex). In the phenotype that was resistant to BFB, no brain changes were seen. Although the investigators have an emerging picture of the brain's role in UUI, the investigators have only rudimentary understanding of what is 'normal', i.e. how the brain normally controls the bladder. Moreover, the investigators do not know whether this control mechanism is the same across the lifespan, or whether it changes owing to the impact of aging. Thus, the investigators aims are to characterize the brain's normal role in bladder control in both young and old people, to determine the changes in brain structure and function that lead to bladder control failure (UUI), and to examine how such changes differ between young and old individuals. To address the aims, the investigators will utilize detailed neuroimaging to evaluate 80 asymptomatic women and 80 women with UUI, each group divided into young (18-45) and old (65+ years) individuals. The study will enable the investigators to define the brain's key structures, functional activity, and mechanisms involved in normal bladder control, and to identify the differences in these elements among those with UUI, both young and old.

By elucidating the mechanisms that mediate the brain's control (and loss of control) of bladder function, the proposed study should enhance the investigators working model, deepen the understanding of the impact of aging, and identify better targets for the treatment of UUI. It may thereby enable scientists to develop novel and more effective new therapies based on the revolution in neuroscience-and more hope for UUI sufferers.

03

Conditions studied

  • Urgency Urinary Incontinence

Browse trials for

Keywords

  • Urinary Incontinence
  • Urgency urinary incontinence
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 'Old' (community-dwelling, mentally and functionally intact ambulatory women aged 65+ years) or 'Young' (equivalent women aged 18-45)
  • 'Wet' (those who meet the International Continence Society definition of urgency urinary incontinence (urinary leakage accompanied by a sudden, strong urge to void which is difficult to defer) >5 times per week, for 3 months despite treatment for reversible causes (e.g., Urinary tract infection) and confirmed by a mean of one episode per day of UUI on 3-day bladder diary) or 'Dry' (women without current or past UUI or other lower urinary tract symptoms.) Infrequent stress incontinence of a small amount is acceptable.
  • Urge-predominant mixed incontinence is acceptable provided the subject is able to differentiate between stress incontinence (SUI - leakage that coincides instantaneously with cough, laugh, exercise) and urgency incontinence, i.e., leakage accompanied by a sudden strong urge to void that is difficult to defer.
  • Those with current or previous use of anticholinergic/beta-3 agonist medications will be considered for the study if they are willing to go through a of at least 4 weeks of duration.

Exclusion criteria

Exclusion Criteria:

Dry Groups

  • Current or prior treatment for UUI
  • Leakage on bladder diary not ascribed to minimal SUI (see bullet above)

All Groups: 'Wet' or 'Dry'; 'Young' or 'Old'

  • Cognitive impairment:

    • \<26
    • inability to perform a voiding diary/pad test
    • inability to reliably take daily medication
    • inability to comply with fMRI testing
  • Impaired mobility

    o Timed up and go test ≥ 12 secs

  • Medical instability:

    • severe uncontrolled hypertension >180mmHg systolic or >100mmHg diastolic
    • potential major changes in medical management over the course of the study period (i.e. upcoming surgery/treatment)
    • frailty according to the Fried criteria
  • MRI incompatibility:

    • metal implants
    • claustrophobia
    • unidentified/untested compatibility of metal implants
  • Medication incompatibility:

    • allergy to study medication (all prophylactic antibiotic choices)
    • interaction of prophylactic antibiotic choices with current medications
    • expected change in medication during the study
  • Neurological conditions:

    • spinal cord injury;
    • multiple sclerosis
    • clinically apparent lesions (e.g. lacunae associated with stroke)
    • prior stroke
    • Parkinson's Disease/ALS/MSA
    • any clinically apparent neurological condition
  • Lower urinary tract comorbidities/treatment:

    • history of pelvic irradiation
    • bladder or advanced uterine cancer
    • possible urethral obstruction (advanced prolapse [POP-Q>II] or Qmax\<12 ml/s on free flow)
    • urinary retention (PVR >200 ml)
    • Interstitial Cystitis/Bladder Pain Syndrome
    • artificial sphincter implant
    • Botox treatment for UUI within 1 year
    • Neuromodulation treatment for UUI
  • Other comorbidities:

    • uncontrolled depression (PHQ-9 ≥10)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
217 participants (actual)

Study arms

  • Experimental
    Brain functional MRI with simplified urodynamics

    Females with urgency urinary incontinence

    Other: Brain functional MRI with simplified urodynamics

Interventions

  • OtherBrain functional MRI with simplified urodynamics

    Structural: MPRAGE provides a structural image, which is used for coregistration of subjects. Structural scans are then performed including Diffusion Spectrum Imaging (DSI; microstructural), and Fluid-attenuated inversion recovery (FLAIR; white matter specific) scans. Functional: With about 50 ml in the bladder, resting state functional BOLD measurements are made, followed by functional whole-brain images while a small amount of saline is infused and withdrawn from the bladder, in 2 blocks of 4 repetitions each. Each repetition starts with a 12-scan pause, followed by infusion (6 scans = 12 s), pause (6 scans), and withdrawal (6 scans). Each block of 4 repetitions is completed by a 6 scan pause during which scanning continues. 24 ml is infused at 120 ml/min, and slightly less is withdrawn to avoid accommodation.This is repeated on an empty and full bladder along with a resting state image.

06

What researchers measure

Primary outcomes

  1. BOLD (Blood Oxygen Level Dependent) fMRI Signal Contrast - mPFC

    BOLD signal contrast - voxel-wise subtraction of normalized brain activity signal measure (BOLD response) during bladder fluid withdrawal from that during bladder infusion in the a priori defined mPFC (medial prefrontal cortex) region. Since BOLD signal represents the normalized contrast in fMRI signal between two states as a proxy for cerebral blood flow, it does not have a unit. The beta value represents the amplitude of the BOLD signal difference between the two conditions. A larger beta value represents a larger difference in activity. Negative values represent greater activity in the 'withdrawal' condition.

    Time frame: Baseline

  2. BOLD (Blood Oxygen Level Dependent) fMRI Signal Contrast - Left Insula

    BOLD signal contrast - voxel-wise subtraction of normalized brain activity signal measure (BOLD response) during bladder fluid withdrawal from that during bladder infusion in the a priori defined insula region. Since BOLD signal represents the normalized contrast in fMRI signal between two states as a proxy for cerebral blood flow, it does not have a unit. The beta value represents the amplitude of the BOLD signal difference between the two conditions. A larger beta value represents a larger difference in activity. Negative values represent greater activity in the 'withdrawal' condition.

    Time frame: Baseline

  3. BOLD (Blood Oxygen Level Dependent) fMRI Signal Contrast - dACC

    BOLD signal contrast - voxel-wise subtraction of normalized brain activity signal measure (BOLD response) during bladder fluid withdrawal from that during bladder infusion in the a priori defined dACC (dorsal anterior cingulate cortex) region. Since BOLD signal represents the normalized contrast in fMRI signal between two states as a proxy for cerebral blood flow, it does not have a unit. The beta value represents the amplitude of the BOLD signal difference between the two conditions. A larger beta value represents a larger difference in activity. Negative values represent greater activity in the 'withdrawal' condition.

    Time frame: Baseline

07

Results

Posted Oct 5, 2026

Participant flow

Participants recruited to single University of Pittsburgh site using online research registries and local geriatrics and urology clinics.

Participant flow — Overall Study
MilestoneYoung DryYoung WetOld DryOld Wet
Started52674751
Completed41404042
Not completed112779

Outcome measures

PrimaryBOLD (Blood Oxygen Level Dependent) fMRI Signal Contrast - mPFC

BOLD signal contrast - voxel-wise subtraction of normalized brain activity signal measure (BOLD response) during bladder fluid withdrawal from that during bladder infusion in the a priori defined mPFC (medial prefrontal cortex) region. Since BOLD signal represents the normalized contrast in fMRI signal between two states as a proxy for cerebral blood flow, it does not have a unit. The beta value represents the amplitude of the BOLD signal difference between the two conditions. A larger beta value represents a larger difference in activity. Negative values represent greater activity in the 'withdrawal' condition.

Time frame:
Baseline
Reported as:
Mean · beta value (no units)
BOLD (Blood Oxygen Level Dependent) fMRI Signal Contrast - mPFC
beta value (no units)Young DryYoung WetOld DryOld Wet
BOLD (Blood Oxygen Level Dependent) fMRI Signal Contrast - mPFC-0.1960800 ± 0.3793670-0.1141890 ± 0.5451350-0.1688894 ± 0.3134661-0.1224623 ± 0.3120977
PrimaryBOLD (Blood Oxygen Level Dependent) fMRI Signal Contrast - Left Insula

BOLD signal contrast - voxel-wise subtraction of normalized brain activity signal measure (BOLD response) during bladder fluid withdrawal from that during bladder infusion in the a priori defined insula region. Since BOLD signal represents the normalized contrast in fMRI signal between two states as a proxy for cerebral blood flow, it does not have a unit. The beta value represents the amplitude of the BOLD signal difference between the two conditions. A larger beta value represents a larger difference in activity. Negative values represent greater activity in the 'withdrawal' condition.

Time frame:
Baseline
Reported as:
Mean · beta value (no units)
BOLD (Blood Oxygen Level Dependent) fMRI Signal Contrast - Left Insula
beta value (no units)Young DryYoung WetOld DryOld Wet
BOLD (Blood Oxygen Level Dependent) fMRI Signal Contrast - Left Insula0.14190175 ± 0.27006470.14075584 ± 0.39714820.02884665 ± 0.22198770.11903335 ± 0.2174073
PrimaryBOLD (Blood Oxygen Level Dependent) fMRI Signal Contrast - dACC

BOLD signal contrast - voxel-wise subtraction of normalized brain activity signal measure (BOLD response) during bladder fluid withdrawal from that during bladder infusion in the a priori defined dACC (dorsal anterior cingulate cortex) region. Since BOLD signal represents the normalized contrast in fMRI signal between two states as a proxy for cerebral blood flow, it does not have a unit. The beta value represents the amplitude of the BOLD signal difference between the two conditions. A larger beta value represents a larger difference in activity. Negative values represent greater activity in the 'withdrawal' condition.

Time frame:
Baseline
Reported as:
Mean · beta value (no units)
BOLD (Blood Oxygen Level Dependent) fMRI Signal Contrast - dACC
beta value (no units)Young DryYoung WetOld DryOld Wet
BOLD (Blood Oxygen Level Dependent) fMRI Signal Contrast - dACC0.06615236 ± 0.29869240.15198950 ± 0.4791248-0.08932060 ± 0.27510530.05305285 ± 0.2561589

Adverse events

Collected over Adverse event data was collected during study visit with intervention (MRI), i.e., the 3-4 hour visit that included catheterization and an MRI, and up to 3 days later.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Young Dry0/41 (0%)2/41 (4.9%)4/41 (9.8%)
Young Wet0/40 (0%)0/40 (0%)2/40 (5%)
Old Dry0/40 (0%)0/40 (0%)1/40 (2.5%)
Old Wet0/42 (0%)1/42 (2.4%)0/42 (0%)
Most frequent serious events
Most frequent serious events
EventYoung DryYoung WetOld DryOld Wet
10028050Nervous system disorders2/410/400/401/42
Most frequent other events
Most frequent other events
EventYoung DryYoung WetOld DryOld Wet
10037175Nervous system disorders4/412/401/400/42

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Young DryYoung WetOld DryOld WetTotal
<=18 years00000
Between 18 and 65 years41400081
>=65 years00404282
Age, Continuous
Age, Continuous(years)Young DryYoung WetOld DryOld WetTotal
Mean32.6 ± 7.536.4 ± 6.769.4 ± 3.572.1 ± 5.452.7 ± 10.2
Sex: Female, Male
Sex: Female, Male(Participants)Young DryYoung WetOld DryOld WetTotal
Female41404042163
Male00000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Young DryYoung WetOld DryOld WetTotal
Hispanic or Latino12003
Not Hispanic or Latino40383941158
Unknown or Not Reported00112
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Young DryYoung WetOld DryOld WetTotal
American Indian or Alaska Native00000
Asian31004
Native Hawaiian or Other Pacific Islander00000
Black or African American492520
White30263836130
More than one race33017
Unknown or Not Reported11002
Region of Enrollment
Region of Enrollment(participants)Young DryYoung WetOld DryOld WetTotal
United States41404042163
No of leaks/24h
No of leaks/24h(leaks /24hours on 3 day bladder diary)Young DryYoung WetOld DryOld WetTotal
Mean0 ± 03.79 ± 2.260 ± 03.97 ± 2.131.95 ± 2.48
BMI
BMI(kg/m^2)Young DryYoung WetOld DryOld WetTotal
Mean27.5 ± 7.833.2 ± 7.925.4 ± 5.233.1 ± 13.429.8 ± 9.7

1 further baseline measures are reported on the registry.

08

Study locations

1 site
  • University of Pittsburgh
    Pittsburgh, Pennsylvania 15213, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — All of the individual participant data collected during the trial, after de-identification may be shared with other researchers.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Following publication, no end date

Access criteria: Any purpose

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Jul 2025, 55 months.

Results were first posted in Oct 2026, 1 year 2 months after primary completion.

Of 303 non-industry interventional studies with no phase under Urinary Incontinence, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's 55 months is above that.

Counting every sponsor, half of 366 studies reached it within 15 months; a quarter within 7 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2020
First posted
Oct 22, 2020
StartActual
Dec 14, 2020
Primary completionActual
Jul 31, 2025
CompletionActual
Apr 1, 2026
Results first posted
Oct 5, 2026
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 5, 2026
Enrollment
207→217
Oct 5, 2026
Primary outcomes
3 edited
What changed in the outcomes
  • EditedBOLD (Blood oxygen level dependentOxygen Level Dependent) fMRI signal contrastSignal Contrast - mPFCTime frame: Baseline
  • EditedBOLD (Blood oxygen level dependentOxygen Level Dependent) fMRI signal contrastSignal Contrast - insulaLeft InsulaTime frame: Baseline
  • EditedBOLD (Blood oxygen level dependentOxygen Level Dependent) fMRI signal contrastSignal Contrast - dACCTime frame: Baseline
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Results posted
    Enrollment 207→217
    Primary outcomes 3 edited
    What changed in the outcomes
    • EditedBOLD (Blood oxygen level dependentOxygen Level Dependent) fMRI signal contrastSignal Contrast - mPFCTime frame: Baseline
    • EditedBOLD (Blood oxygen level dependentOxygen Level Dependent) fMRI signal contrastSignal Contrast - insulaLeft InsulaTime frame: Baseline
    • EditedBOLD (Blood oxygen level dependentOxygen Level Dependent) fMRI signal contrastSignal Contrast - dACCTime frame: Baseline
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04599088
Responsible party
Becky Clarkson (Research Assistant Professor of Medicine, University of Pittsburgh) — Principal investigator
First posted
Oct 22, 2020
Start date
Dec 14, 2020
Primary completion
Jul 31, 2025
Completion
Apr 1, 2026
Results posted
Oct 5, 2026
Last update
Oct 5, 2026

Study contacts

Becky Clarkson, PhD
principal investigator · University of Pittsburgh

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion